Skip to Content

Eric S. Yvon, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Technical Director, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2008 EPHE, University of Paris, La Sorbonne, Paris, France, PHD, Summa cum laude, Immunology
1999 EPHE, University of Paris, La Sorbonne, Paris, France, MSc, Summa cum laude, Immunology
1987 ESBB, University of Paris, Paris, France, BS, Cum laude, Biology and Biochemistry


Academic Appointments

Senior Research Scientist, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2013
Instructor, Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, 2010-2012
Research Associate, Baylor College of Medicine Center for Cell and Gene Therapy, Houston, TX, 2000-2010
Research Associate, Necker-EM Hospital, Cell and Gene Therapy Laboratory, Paris, France, 1999-2000
Research Assistant, Necker-EM Hospital, Immunology and Hematology Laboratory, Paris, France, 1990-1999

Selected Publications

Peer-Reviewed Original Research Articles

1. Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant 0(6):793-9, 6/2014. e-Pub 4/2014. PMCID: PMC4080423.
2. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM. Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity. Clin Cancer Res 20(8):2215-25, 4/2014. e-Pub 2/2014. PMCID: PMC3989436.
3. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res 20(4):962-71, 2/2014. e-Pub 12/2013. PMCID: PMC3944408.
4. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100, 1/2014. e-Pub 10/2013. PMID: 24480547.
5. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottachalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in Glioblastoma. Mol Ther 21(11):2087-101, 11/2013. e-Pub 8/13/2013. PMCID: PMC3831041.
6. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 10/2013. PMCID: PMC3800010.
7. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23):6050-6, 12/1/2011. e-Pub 10/7/2011. PMCID: PMC3234664.
8. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 19(12):2239-48, 12/2011. e-Pub 8/30/2011. PMCID: PMC3242659.
9. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 28(6):1107-15, 6/2010. PMCID: PMC3290395.
10. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17(10):1779-87, 10/2009. e-Pub 6/16/2009. PMCID: PMC2835000.
11. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 15(18):5852-60, 9/15/2009. e-Pub 9/8/2009. PMCID: PMC2745508.
12. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 31(9):812-9, Nov-Dec, 11/2008. PMID: 18833006.
13. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264-70, 11/2008. e-Pub 11/2/2008. PMCID: PMC2749734.
14. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 30(2):227-33, Feb-Mar, 2/2007. PMID: 17471169.
15. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11(19 Pt 1):6916-23, 10/1/2005. PMID: 16203783.
16. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood 104(1):26-33, 7/1/2004. e-Pub 3/16/2004. PMID: 15026316.
17. Yvon ES, Vigouroux S, Rousseau RF, Biagi E, Amrolia P, Dotti G, Wagner HJ, Brenner MK. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 102(10):3815-21, 11/15/2003. e-Pub 7/3/2003. PMID: 12842995.
18. Vigouroux S, Yvon E, Wagner HJ, Biagi E, Dotti G, Sili U, Lira C, Rooney CM, Brenner MK. Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol 77(20):10872-80, 10/2003. PMCID: PMC224961.
19. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 14(6):545-59, 4/10/2003. PMID: 12718765.
20. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669-72, 4/28/2000. PMID: 10784449.

Grant & Contract Support

Title: Utilizing TGF-beta Resistant Natural Killer Cells For Adoptive Transfer to Overcome Tumor Immune Evasion
Funding Source: Children's National/PRCP
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2017
Title: Development of NK-based cell therapy for Malignant Peritoneal Mesothelioma
Funding Source: Mesothelioma Applied Research Foundation
Role: Principal Investigator
Duration: 1/1/2015 - 12/31/2017
Title: Engineered Cord Blood NK Cells to Express Interleukin-15 (IL-15) to enhance Anti-Mesothelioma activity
Funding Source: IRG
Role: Principal Investigator
Duration: 12/1/2014 - 11/30/2015
Title: Moon Shot In High-Risk Multiple Myeloma
Funding Source: MD Anderson Cancer Center
Role: Co-Investigator
Principal Investigator: Robert Orlowski
Duration: 9/1/2014 - 8/31/2015
Title: Cord-Blood-Derived Natural Killer Cells as a Novel Therapeutic Strategy for Leukemia
Funding Source: National Institutes of Health
Role: Co-Investigator
Principal Investigator: Katy Rezvani
Duration: 7/1/2014 - 6/30/2019
Title: All-In-One Purification and Engineering of Therapeutic Cell Systems
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Lapotko
Duration: 4/1/2014 - 3/31/2016
Title: Targeting Breast Cancer Stem Cells
Funding Source: Breast Cancer Research Foundation
Role: Co-Leader
Principal Investigator: Andreeff
Duration: 10/1/2013 - 9/30/2014
Title: Regulation and Targeting of GD2+ Breast Cancer Stem-Like Cells - Project 3
Funding Source: MD Anderson Institutional Support
Role: Co-Leader PP-3
Principal Investigator: Andreeff
Duration: 7/1/2013 - 6/30/2016
Title: Cellular Therapy of Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Project 4 Co-Investigator (Baylor)
Principal Investigator: Brenner
Duration: 7/1/2011 - 6/30/2016
Title: Generation of human amniotic fluid stem cell lines with hematopoietic, differentiation potential
Funding Source: Virginia and L.E. Simmons Family Foundation
Role: Co-Investigator
Principal Investigator: Brenner
Duration: 3/15/2011 - 3/14/2012
Title: Improving Cord Blood Transplantation
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Shpall/Bollard
Duration: 2011 - 2016

Last updated: 9/24/2015